Synta Pharmaceuticals Announces First Patient Treated in Phase 1/2 ... - MarketWatch

Synta Pharmaceuticals Announces First Patient Treated in Phase 1/2 ... MarketWatch - 8 hours ago Elesclomol is a first-in-class investigational drug, believed to work by exploiting a fundamental vulnerability of many cancer cells -- their elevated level ... Synta tests prostate-cancer therapy Bizjournals.com all 14 news articles

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 ... - MarketWatch

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 ... MarketWatch - 3 hours ago We believe BZL101 may be an important new anticancer agent because its biological selectivity allows the drug to kill cancer cells without affecting normal ... Cougar Biotechnology Announces Initiation of Phase I/II Trial of ... MarketWatch all 23 news articles

Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects - MarketWatch

Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects MarketWatch - 5 hours ago Because chemotherapy attacks not only cancer cells, but all cells, oftentimes cancer patients must stop treatment due to chemotherapy side effects. ...

New Platinum-phosphate Compounds Kill Ovarian Cancer Cells, Other ... - Science Daily (press release)

SeniorJournal.com

New Platinum-phosphate Compounds Kill Ovarian Cancer Cells, Other ... Science Daily (press release) - Nov 19, 2008 19, 2008) — A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less ... Two New Compounds Show Promise For Eliminating Breast Cancer Tumors Science Daily (press release) all 21 news articles

Stopping Germs From Ganging Up On Humans - Science Daily (press release)

Stopping Germs From Ganging Up On Humans Science Daily (press release) - 5 hours ago He is currently collaborating with cancer biologists to attack chemicals that allow cancer cells to gang up on normal cells. One type of chemical, ...